Phaseline

Targets › TNNC1

TNNC1 (Troponin C, slow skeletal and cardiac muscles): drug programs, companies and trials

1 program from 1 company in 4 trials: 3 Phase 3, 1 Phase 4; Cardiovascular, Other; next expected readout Jun 2028.

Troponin is the central regulatory protein of striated muscle contraction. Tn consists of three components: Tn-I which is the inhibitor of actomyosin ATPase, Tn-T which contains the binding site for tropomyosin and Tn-C. The binding of calcium to Tn-C abolishes the inhibitory action of Tn on actin filaments. (UniProt, P63316)

Open in Phaseline: the race on TNNC1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Tenax TherapeuticsLevosimendan (TNX-103)
Phosphodiesterase 3 inhibitor; Troponin, cardiac muscle positive modulator
PDE3A, PDE3B, TNNC1, TNNI3, TNNT2Phase 3Pulmonary Hypertension Associated With HFpEF; Pulmonary Hypertension; Mechanical Ventilation; Cardiogenic ShockJun 2028

Conditions

Pulmonary Hypertension Associated With HFpEF (1) Pulmonary Hypertension (1) Mechanical Ventilation (1) Cardiogenic Shock (1)

Modalities

small molecule (1)

Companies

Tenax Therapeutics (1)

Related targets

PDE3A (1) PDE3B (1) TNNI3 (1) TNNT2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.